Literature DB >> 24308776

Estimating numbers of persons with persistent hepatitis B virus infection transmitted vertically and horizontally in the birth cohort during 1950-1985 in Japan.

Tomoki Sato1, Son Huy Do, Takako Asao, Tomoyuki Akita, Keiko Katayama, Kozo Tatara, Yuzo Miyakawa, Junko Tanaka.   

Abstract

AIM: We estimated numbers of persons, born between 1950 and 1985 in Japan, who were persistently infected with hepatitis B virus (HBV) through vertical and horizontal infections.
METHODS: HBV carrier rates with vertical and horizontal infections were computed using sex- and age-specific prevalence rates of hepatitis B surface antigen (HBsAg) and hepatitis B e-antigen (HBeAg) by mathematical model. Probabilities of vertical HBV transmission in babies born to carrier mothers with and without HBeAg were presumed to be 90% and 10%, respectively.
RESULTS: HBV carrier rates with vertical infection stayed contrast at approximately 0.3% in birth cohorts through 36 years (1950-1985), both in men and women. By a remarkable constant, HBV carrier rates with horizontal infection decreased steadily from 1.43% to 0.10% in men and from 0.95% to 0.03% in women. The estimated total number of HBV carriers born between 1950 and 1985 was 522 500 (355 488-693 606). Of them, the numbers of HBV carriers with vertical and horizontal infections were 197 574 (149 505-288 709) and 324 926 (205 983-404 896); they accounted for 37.81% and 62.19%, respectively, with a ratio of 1:1.64. The ratio between vertical and horizontal infections was 1:2.20 in men and 1:1.06 in women.
CONCLUSION: Vertical HBV infection had stayed constant until immunoprophylaxis of mother-to-baby transmission was implemented in 1986 in Japan. In contrast, horizontal HBV infection decreased over years. The decrease would be due to many factors, including improved socioeconomic environments, advanced medical maneuvers and equipment, and careful vaccination procedures.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  hepatitis B e-antigen; hepatitis B virus carrier; horizontal infection; newborns; vertical infection

Year:  2014        PMID: 24308776     DOI: 10.1111/hepr.12288

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study.

Authors:  Junko Tanaka; Akemi Kurisu; Masatsugu Ohara; Serge Ouoba; Masayuki Ohisa; Aya Sugiyama; Michelle L Wang; Lindsey Hiebert; Tatsuya Kanto; Tomoyuki Akita
Journal:  Lancet Reg Health West Pac       Date:  2022-03-16

2.  Hepatitis B Virus Infection among Japanese Immigrants and Descendants: The Need to Strengthen Preventive and Control Measures.

Authors:  Luiz Henrique Ferraz Demarchi; Larissa Melo Bandeira; Deborah Ledesma Taira; Marina Castilhos Souza Umaki Zardin; Mary Luizia Ibanhes; Ana Olivia Pascoto Esposito; Larissa Domingues Castilho De Arruda; Crhistinne Cavalheiro Maymone Gonçalves; Sabrina Moreira Dos Santos Weis-Torres; Gabriela Alves Cesar; Rivaldo Venâncio Da Cunha; Tayana Serpa Ortiz Tanaka; Marco Antonio Moreira Puga; Grazielli Rocha De Rezende; Roberta Barbosa Lopes; Silvia Naomi de Oliveira Uehara; João Renato Rebello Pinho; Flair Jose Carrilho; Michele Soares Gomes-Gouvêa; Ana Rita Coimbra Motta-Castro
Journal:  Viruses       Date:  2022-05-18       Impact factor: 5.818

Review 3.  Is mother-to-infant transmission the most important factor for persistent HBV infection?

Authors:  Zixiong Li; Xiaomei Hou; Guangwen Cao
Journal:  Emerg Microbes Infect       Date:  2015-05-20       Impact factor: 7.163

Review 4.  Host Genetic Determinants of Hepatitis B Virus Infection.

Authors:  Zhenhua Zhang; Changtai Wang; Zhongping Liu; Guizhou Zou; Jun Li; Mengji Lu
Journal:  Front Genet       Date:  2019-08-13       Impact factor: 4.599

Review 5.  Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view.

Authors:  Junko Tanaka; Tomoyuki Akita; Ko Ko; Yoshihiko Miura; Masahiro Satake
Journal:  Hepatol Res       Date:  2019-08-22       Impact factor: 4.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.